Engflag

Zatamil

Quick links to important sections

Zatamil

Zatamil_DE

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zatamil

Property Description
Active ingredient Mometasone Furoate
Form Aqueous nasal spray suspension
Pharmacological class Glucocorticosteroid
General Purpose Localized anti-inflammatory action
Origin Synthetic compound

Zatamil: Definition and Classification as a Glucocorticosteroid

Zatamil is a prescription-only medicine that utilizes the active ingredient Mometasone Furoate, a potent, synthetic compound classified within the pharmacological group of glucocorticosteroids. This classification identifies the medicine as an anti-inflammatory agent, utilized for targeting inflammatory processes underlying nasal discomfort. As a synthetic corticosteroid, Mometasone Furoate is characterized by pharmacological properties demonstrating a high affinity for glucocorticoid receptors, allowing for action at the site of inflammation.

Composition, Form, and General Anti-Inflammatory Purpose

The medicine is delivered as a single-ingredient aqueous nasal spray suspension, specifically designed for direct, localized application via the intranasal route. This form is distinct from oral medications, ensuring the Mometasone Furoate is concentrated onto the nasal lining. The use of this localized form is intended for achieving targeted therapeutic effects, which is a key differentiating factor from systemic medications. This structure confirms that the spray's design is optimized to provide local relief while minimizing systemic exposure. By leveraging this localized anti-inflammatory effect, Zatamil helps to dampen the allergic cascade and reduce the physical symptoms of irritation and swelling caused by conditions where an inflammatory response is the primary cause of discomfort.

What side effects are possible with Zatamil?

Possible side effects and safety information

The safety profile for Zatamil (Mometasone Furoate) is based on classifications established by government regulatory bodies, detailing adverse reactions by frequency and affected organ system.

Official Adverse Reactions and Frequencies

Adverse reactions are officially grouped by how often they occur:

  • Very Common: Epistaxis (nosebleed).
  • Common: Headache, nasal burning, nasal irritation, pharyngitis, and nasal ulceration.
  • Not Known: This category, where frequency cannot be estimated from available data, includes hypersensitivity reactions (such as angioedema and anaphylactic reaction), glaucoma, cataracts, and nasal septum perforation.

Reactions are classified into System-Organ Classes including Respiratory, thoracic and mediastinal disorders and Nervous system disorders.

Serious Adverse Reactions and Safety Constraints

The regulatory labeling includes specific warnings regarding potentially serious adverse reactions and safety constraints.

Serious Potential: Prolonged use, particularly at high doses, carries the potential for systemic corticosteroid effects, including HPA axis suppression and Cushingoid features. Ocular issues such as glaucoma and cataracts are also documented as potential risks associated with long-term exposure.

Population and Duration Patterns: Safety constraints mandate that growth rate in pediatric patients should be monitored during prolonged treatment. Localized side effects, such as nasal irritation, often appear more frequently at the start of treatment.

Restrictions: The medicine is contraindicated for use in the presence of an untreated localized infection of the nasal mucosa. Use is also advised against until healing is complete in individuals with recent nasal surgery or trauma, due to the risk of impaired wound healing.

Overdose and Emergency Response

The official regulatory profile for Zatamil (Mometasone Furoate nasal spray) is defined by two distinct exposure scenarios: acute ingestion and chronic misuse. Acute overdose is generally classified as low risk due to the drug's limited systemic absorption; the systemic bioavailability of the active ingredient is documented as less than 1%. Consequently, official guidance states that acute overdose events are typically unlikely to require any specific therapy beyond observation.

The primary documented physiological manifestation associated with excessive exposure to this class of drug is the suppression of HPA (Hypothalamic-Pituitary-Adrenal) axis function. This risk is specifically constrained to long-term misuse, not acute events.

When to Seek Immediate Medical Help

Immediate medical attention must be sought if there are clinical signs consistent with clinically significant adrenal suppression. This serious outcome is formally documented to result from the use of higher than recommended dosages for prolonged periods and represents a severe systemic consequence.

For acute, isolated overdose incidents where immediate medical help is not indicated, the mandated management following observation is to subsequently initiate the appropriate prescribed dosage. Regulatory documents also note a specific concern for pediatric patients who use doses above the recommended limit for extended periods, placing them at risk for documented growth reduction or suppression.

Therapeutic Uses of Zatamil

What Zatamil Treats: Main Uses and Benefits

Zatamil (mometasone furoate) is utilized for the symptomatic management of skin conditions that are responsive to topical corticosteroids. This medication is typically employed for short-term use in clinical scenarios involving acute inflammatory flares.

The medication's primary therapeutic role is to address the signs and symptoms associated with specific dermatoses. It is intended to help reduce the discomfort, redness, and swelling experienced by the patient. The benefit is the temporary moderation of these visible and bothersome manifestations, which supports the overall treatment plan.

Indications include addressing the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as psoriasis and atopic dermatitis.

“The treatment is intended to help with symptomatic relief from itching and inflammation.”

Quick Fact: Intended for Symptomatic Relief

Regulatory References

  1. FDA Prescribing Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Zatamil?

Eligibility for Zatamil (Mometasone Furoate Nasal Spray) is strictly defined by regulatory documents, which establish specific age limits, contraindications, and populations requiring restricted use. The medicine is primarily intended for use by adults and adolescents aged 12 years and older, as well as children aged 2 years and older for certain indications, such as allergic rhinitis. Use in children under 2 years of age is not established and is generally not recommended by regulators.

Absolute Non-Eligibility

Zatamil is contraindicated in patients with a known hypersensitivity to the medicine or its ingredients. It must not be used in the presence of localized untreated nasal infections (e.g., Herpes Simplex) or in patients who have recently undergone nasal surgery or trauma until the nasal passages have fully healed.

Conditional Use and Restrictions

Official labeling mandates caution or restriction for several populations:

  • Infectious Conditions: Use is restricted in patients with active or quiescent tuberculosis of the respiratory tract or those with untreated systemic fungal, bacterial, or viral infections.
  • Pregnancy and Lactation: Use is not recommended during pregnancy unless the potential benefit justifies the risk. Breastfeeding women should exercise caution.
  • Organ Function: While specific restrictions are not universally mandated, patients with hepatic impairment should use the medicine with caution.

What should I know about interactions with other medicines?

The officially documented interaction profile for Zatamil (Mometasone Furoate Nasal Spray) is limited due to the product's minimal systemic absorption following intranasal administration, as confirmed in regulatory documents.

Interaction Scope and Classification

The primary potential for drug-drug interaction is pharmacokinetic in nature. Official prescribing information states that Mometasone Furoate is metabolized by the Cytochrome P450 (CYP) 3A4 enzyme. This metabolic pathway establishes the context for potential interactions with other medicines.

Co-administration of Zatamil with medicinal products classified as strong inhibitors of CYP3A4 is the only type of interaction formally documented as clinically relevant. This interaction is consistently classified as leading to Increased Systemic Exposure (elevated plasma concentrations) of Mometasone Furoate. Substances like Ketoconazole were used in clinical studies to confirm this modification of drug exposure. Formal contraindicated combinations are generally not specified in official labeling for this nasal spray formulation.

Regulatory Constraints

Regulatory documents do not detail any required timing-based separation rules for Zatamil administration. Furthermore, interactions with food, alcohol, herbal products, or supplements are not formally documented in the official regulatory summaries. The core regulatory constraint is the documented increase in systemic exposure when the product is co-administered with strong CYP3A4 inhibitors.

Mechanism of Action

Zatamil operates as a positive allosteric modulator of the inhibitory GABA A receptor complex, a ligand-gated ion channel. The molecule binds to a distinct, non-GABA site located specifically at the interface between the alpha 1 and gamma 2 subunits of the receptor. This interaction induces a conformational change in the receptor structure, increasing the affinity of the receptor for the neurotransmitter GABA.

The stabilized receptor facilitates the opening of the integral chloride ion channel. The consequent influx of Cl^- ions across the postsynaptic neuronal membrane leads to hyperpolarization of the neuron. This change in membrane potential functionally decreases the intrinsic excitability of targeted neuronal circuits, primarily those within the central nervous system, resulting in system-level modulation of neuronal firing rates.

Dosage and Administration Information

Instruction Map: How to use Zatamil

Zatamil is an aqueous nasal spray suspension that is administered by the intranasal route only. Usage is defined by parameters which detail the specific dose and frequency based on the patient's age and the condition being managed.

Category Instruction
Route of administration Intranasal (metered spray suspension).
Dosing schedule (Adults/Adolescents) For allergic rhinitis, the recommended dose is two sprays (100 mcg) in each nostril once daily. For nasal polyps, the dose is two sprays in each nostril twice daily (total 400 mcg), or once daily for maintenance.
Age-group administration rules The dose for children aged 2 to 11 years is one spray (50 mcg) in each nostril once daily. Use against nasal polyps is not established for those under 18 years.
Preparation requirements The container must be shaken well before each use. The pump requires priming with 10 actuations before the initial use and must be reprimed if unused for more than one week.
Missed-dose rules If a dose is missed, administer it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Users must not administer a double dose to compensate.
Special procedural conditions The spray must be aimed away from the nasal septum. For prophylaxis of seasonal rhinitis, administration is recommended 2 to 4 weeks before the anticipated start of the pollen season. The device must be discarded after the specified number of metered sprays is used.

Connection to the overall use protocol

This protocol establishes the described approach for using Zatamil at the 50 mcg per spray strength. The instructions define the preparation and delivery technique, ensuring the medicine is administered as a localized nasal treatment. The precise dosing schedules and procedural constraints are intended to support the correct use of the device and adherence to the specified regimen.

Recent Clinical Evidence

Zatamil, a brand formulation of the moderate-to-high potency topical corticosteroid mometasone furoate (0.1%), is indicated for the short-term relief of inflammatory and itchy manifestations of corticosteroid-responsive skin disorders, such as psoriasis and atopic dermatitis (eczema).

Clinical evidence primarily focuses on demonstrating the therapeutic equivalence of the mometasone furoate component across different formulations (ointment, cream, lotion, hydrogel) compared to established topical steroids or different brands. The drug works by activating pathways that reduce inflammation, swelling, and itching in the affected area.

Efficacy and Formulation

Studies comparing a mometasone furoate hydrogel formulation (like Zatamil Hydrogel) to the ointment form have generally shown comparable efficacy in managing conditions like psoriasis and eczema within a short treatment period (e.g., up to four continuous weeks). The hydrogel format is noted in clinical settings to have rapid absorption, offering equivalent anti-inflammatory response at 24 hours compared to the ointment, while potentially improving cosmetic acceptability.

Safety and Tolerability

The safety profile is consistent with other topical corticosteroids of similar potency. Common side effects reported during clinical use include localized skin reactions such as burning, stinging, and itching at the application site, which are usually mild and transient. Less common, but more serious, potential side effects associated with prolonged use or use over large areas include: thinning of the skin (skin atrophy), changes in skin pigmentation, and, rarely, systemic effects such as suppression of the adrenal gland function. Use in children requires careful monitoring by a healthcare professional due to the increased risk of systemic absorption.

Frequently Asked Questions (FAQ)

Common questions about Zatamil (FAQ)

Q: What is the main thing Zatamil is used for?

Official regulatory documents indicate that Zatamil is used for the prevention and treatment of nasal symptoms related to seasonal or perennial allergic rhinitis (common allergies). It is also officially indicated for the treatment of nasal polyps.

Q: What class of drug does Zatamil belong to?

According to the official product information, Zatamil is classified as a glucocorticosteroid. This class of medicine is generally associated with reducing inflammation.

Q: Is Zatamil available over-the-counter or only with a prescription?

Regulatory status information confirms that both prescription (Rx) and over-the-counter (OTC) versions of this nasal spray product are available for purchase.

Q: Can Zatamil be used for temporary relief of symptoms?

Studies and official information indicate that while some individuals may start to feel relief within 12 hours of the first dose, the full benefit is typically achieved after several days of regular, once-a-day use. Regulatory information indicates the full benefit is typically achieved after several days of regular use, emphasizing continuous adherence to the regimen rather than use for immediate, temporary relief.

Q: What does the medicine look like (color, shape, or markings)?

The medicine is supplied as a metered nasal spray suspension. Official product descriptions state that it is an opaque suspension inside the device.

Q: Why is Zatamil only recommended for certain types of patients?

Official labeling dictates that the product is contraindicated for individuals with a known hypersensitivity to the drug, and is not indicated for use in children under two years of age. Warnings also advise caution in patients with an untreated localized nasal infection, or those with recent nasal surgery or trauma.

Q: How quickly does Zatamil usually start to work?

Official documentation states that some patients may begin to experience relief from symptoms within 12 hours after the first dose. However, the full therapeutic effect may take several days of use to fully develop, according to official data.

Q: What are the general expectations for people who use Zatamil?

The regulatory warnings section outlines general expectations, which include the potential for local side effects such as nosebleeds or irritation. The label also addresses potential serious risks, such as vision changes or, in children, a monitored reduction in growth velocity, which may require periodic clinical assessment.

Q: Are the side effects of Zatamil usually mild or severe?

Official side effect information categorizes effects by frequency, noting that common adverse effects include headache, nosebleeds, and sore throat, while more serious effects like glaucoma/cataracts are considered rare and are often associated with long-term use.

Q: Is it normal to feel a headache when first starting Zatamil?

Yes, official regulatory documents list headache as one of the most common adverse reactions reported by individuals in clinical trials.

Q: What are the most commonly reported side effects of Zatamil?

The official product label lists the most frequently reported adverse reactions in clinical trials as headache, nosebleeds (epistaxis), and pharyngitis (sore throat).

Q: Are there any serious or rare side effects listed for Zatamil?

Yes. Regulatory warnings cover rare but serious risks, including the development of a localized Candida infection, nasal septum perforation, or vision issues like glaucoma and cataracts. Systemic effects, such as adrenal suppression, are also listed as a risk.

Q: Can Zatamil cause issues with sleep (insomnia or drowsiness)?

Official product information notes that certain systemic effects of corticosteroids have been linked to rare psychological or behavioral changes, such as sleep disorders or anxiety. Drowsiness itself is not listed as a common effect.

Q: How often do individuals in studies report experiencing side effects from Zatamil?

The official product label provides specific incidence rates and percentages for various adverse reactions, based on how often they were reported by individuals participating in clinical trials.

Q: Is Zatamil permitted for use in people over the age of 65?

The official indication for allergic rhinitis covers treatment in adults, including older patients, which establishes regulatory permission for use in this age group.

Q: Are there specific age limitations for who can use Zatamil?

The product is not indicated for use in children under 2 years of age, and is contraindicated in this population. Furthermore, the safety and effectiveness for treating nasal polyps are not established for individuals who are under 18 years of age.

Q: Can people with a history of liver or kidney problems use Zatamil?

Regulatory documents state that the drug is minimally absorbed systemically. However, its effects have not been formally studied in patients with renal (kidney) impairment. Official documents note that caution may be appropriate in cases of severe hepatic (liver) impairment.

Q: Is Zatamil described as safe for women who are pregnant or planning to become pregnant?

Official labeling directs that individuals who are pregnant or planning to become pregnant are advised to consult a health professional before using the medicine. This is the official guidance provided.

Q: Can a nursing mother safely take Zatamil?

Official regulatory information states that it is unknown if the drug is excreted in human milk. For this reason, official guidance is available only by consultation with a health professional regarding use while nursing.

Q: Are there any specific pre-existing medical conditions that prohibit the use of Zatamil?

The label contraindicates use for those with known hypersensitivity to the medicine. Official warnings indicate the product is generally not intended for use in patients with untreated localized nasal infections (like herpes simplex) or those with certain active systemic infections (such as tuberculosis).

Q: Is there information available about the long-term use of Zatamil?

Yes. The warnings section explicitly addresses risks associated with long-term use. These risks include the potential for nasal septum perforation, reduced growth velocity in children, and the development of conditions like glaucoma or cataracts, which are risks that may require periodic monitoring as part of clinical care.

Q: What do official health agencies say about the overall safety profile of Zatamil?

The official safety profile is defined by the extensive list of warnings, precautions, and adverse reactions documented in the regulatory label. This includes specific information on local nasal effects, potential systemic effects, and risks for specific populations, such as children.

Q: What is the main difference between the immediate-release and extended-release versions of Zatamil?

Official regulatory documents only describe one formulation for this product, which is the aqueous nasal spray suspension. There are no descriptions in the label for immediate-release or extended-release versions of the nasal spray.

Q: Is it necessary to take Zatamil at the exact same time every day?

The product is prescribed for a daily regimen (once or twice daily). The official guidance for a missed dose instructs the user to take it when remembered, unless it is near the next scheduled dose. This information helps establish the intended flexibility of the daily regimen.

Q: What official information is available about stopping the use of Zatamil?

The official label notes that if signs of adrenal suppression or hypercorticism occur, discontinuation is advised to be done slowly. Discontinuation is also recommended if localized infections (like Candida) are found.

How should Zatamil be stored and disposed of?

How to Store and Dispose of Zatamil

Official regulatory documents define specific conditions for storing and disposing of Zatamil (mometasone furoate aqueous nasal spray).

Storage Requirements

Zatamil must be stored at controlled room temperature, maintaining a range of 20 C to 25 C (68 F to 77 F). It is critical to protect the medicine from freezing as this can compromise the suspension and the device. The product must be stored in its original container and the bottle should be kept tightly closed when not in use.

Stability and Child Safety

To maintain efficacy, the nasal spray must be discarded within 2 months after first use, even if some medicine remains in the bottle. All medication must be stored out of the sight and reach of children.

Disposal

Unused or expired Zatamil should be disposed of in accordance with official local regulations. The medicine must not be flushed down a toilet or placed in household garbage; instead, utilize a dedicated medicine take-back program or follow specific governmental disposal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zatamil found in:

A-Z Index: